59507-40-3

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-Bromobenzyl)piperidine is used as a building block for the synthesis of novel drug candidates due to its potential to modulate pharmacological properties. The incorporation of the bromobenzyl group into the piperidine structure can enhance the compound's biological activities, making it a promising candidate for the development of new therapeutic agents with improved efficacy and selectivity.
Used in Medicinal Chemistry Research:
1-(3-Bromobenzyl)piperidine serves as a valuable compound in medicinal chemistry research for exploring its potential applications in drug discovery. Its unique structure and properties allow researchers to investigate its interactions with various biological targets, which can lead to the identification of new drug leads and the optimization of existing drug candidates.

InChI:InChI=1/C12H16BrN/c13-12-6-4-5-11(9-12)10-14-7-2-1-3-8-14/h4-6,9H,1-3,7-8,10H2

Upstream product

• 110-89-4 piperidine 
• 823-78-9 meta-bromobenzyl bromide 
• 3132-99-8 m-bromobenzoic aldehyde 

Downstream Products

• 956593-48-9 2-methyl-4-(4-(methylsulfanyl)phenyl)-7-(3-(piperidin-1-ylmethyl)phenoxy)-1,2,3,4-tetrahydroisoquinoline 
• 956593-61-6 2-methyl-4-(4-(methylsulfanyl)phenyl)-5-(3-(piperidin-1-ylmethyl)phenoxy)-1,2,3,4-tetrahydroisoquinoline 
• 859833-21-9 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperidine 
• 864277-08-7 N-(3’-(piperidin-1-ylmethyl)-[1,1’-biphenyl]-4-yl)sulfonyl-N’-(5-ethoxycarbonylthiazol-2-yl)piperazine 
• 2905-56-8 N-Benzylpiperidine 
• 1086400-79-4 2-methyl-4-(4-(methylsulfanyl)phenyl)-7-(3-(piperidin-1-ylmethyl)phenoxy)-1,2,3,4-tetrahydroisoquinoline trifluoroacetic acid salt 
• 1086400-82-9 2-methyl-4-(4-(methylsulfanyl)phenyl)-5-(3-(piperidin-1-ylmethyl)phenoxy)-1,2,3,4-tetrahydroisoquinoline trifluoroacetic acid salt 
• 1086400-86-3 2-{(methyl)[3-(3-(piperidin-1-ylmethyl)phenoxy)benzyl]amino}-1-(4-methylsulfanyl-phenyl)-ethan-1-one 
• 1086400-87-4 2-{(methyl)[3-(3-(piperidin-1-ylmethyl)phenoxy)benzyl]amino}-1-(4-(methylsulfanyl)phenyl)ethan-1-ol 
• 1086400-85-2 (methyl)[3-(3-(piperidin-1-ylmethyl)phenoxy)benzyl]amine 
• 1086400-84-1 3-[3-(piperidin-1-ylmethyl)phenoxy]benzaldehyde 
• 1432450-90-2 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(3-(piperidin-1-ylmethyl)phenyl)quinazolin-4-amine 
• 1188547-06-9 4-[4-(3-(piperidin-1-ylmethyl)phenyl)but-3-ynyl]morpholine 
• 1086400-83-0 {3-[3-(piperidin-1-ylmethyl)phenoxy]phenyl}methanol 

Relevant academic research and scientific papers

Synthesis of Biaryls Having a Piperidylmethyl Group Based on Space Integration of Lithiation, Borylation, and Suzuki–Miyaura Coupling

In a flow microreactor, aryllithiums bearing a piperidylmethyl group were generated using nBuLi by precise residence time control and effective temperature control, and then selectively borylated with boronic esters such as 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (BpinOiPr) and trimethyl borate B(OMe)3 by fast mixing. Moreover, the direct integration with Suzuki–Miyaura cross coupling were successfully achieved to obtain nitrogen-containing biaryl compounds. The present method could be applied for the straightforward synthesis of the key intermediate of a bioactive component bearing a piperidylmethyl-biphenyl framework.

Bis(het)aryl-1,2,3-triazole quinuclidines as α7 nicotinic acetylcholine receptor ligands: Synthesis, structure affinity relationships, agonism activity, [18F]-radiolabeling and PET study in rats

In this paper we describe the design and synthesis of bis(Het)Aryl-1,2,3-triazole quinuclidine α7R ligands using an efficient three-step sequence including a Suzuki-Miyaura cross coupling reaction with commercially available and home-made boron derivatives. The exploration of SAR required the preparation of uncommon boron derivatives. Forty final drugs were tested for their ability to bind the target and nine of them exhibited Ki values below nanomolar concentrations. The best scores were always obtained when the 5-phenyl-2-thiophenyl core was attached to the triazole. The selectivity of these compounds towards the nicotinic α4β2 and serotoninergic 5HT3 receptors was assessed and their brain penetration was quantified by the preparation and in vivo evaluation of two [18F] radiolabelled derivatives. It can be expected from our results that some of these compounds will be suitable for further developments and will have effects on cognitive disorders.

Palladium(ii)-catalysed ortho-arylation of N-benzylpiperidines

PdII-catalysed ortho-arylation of benzylic heterocycles with arylboronic acid pinacol esters (Ar-BPin) via directed C-H bond activation to generate the desired biaryl products is reported. This methodology is efficient and applicable to a wide range of functionalised Ar-BPin and benzylic heterocycles, allowing the direct synthesis of important biaryl motifs in modest to good yield. This journal is

DIARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AS HISTAMINE H3RECEPTOR AND SEROTONIN TRANSPORTER MODULATORS

Certain diaryl-substituted tetrahydroisoquinoline compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.

Dual serotonin transporter inhibitor/histamine H3 antagonists: Development of rigidified H3 pharmacophores

A series of tetrahydroisoquinolines acting as dual serotonin transporter inhibitor/histamine H3 antagonists is described. The introduction of polar aromatic spacers as part of the histamine H3 pharmacophore was explored. A convergent synthesis of the final products allowing late stage introduction of the aromatic side chain was developed. In vitro and in vivo data are discussed.